Follow us on Twitter
twitter icon@FreshPatents


Factor Viii patents

      

This page is updated frequently with new Factor Viii-related patent applications.




 Nucleic acid encoding bispecific antibodies patent thumbnailNucleic acid encoding bispecific antibodies
Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
Chugai Seiyaku Kabushiki Kaisha


 Factor viii molecules with reduced vwf binding patent thumbnailFactor viii molecules with reduced vwf binding
The present invention relates to a recombinant factor viii molecule, wherein said molecule has reduced vwf binding capacity, and wherein said molecule is covalently conjugated with at least one side group.. .
Novo Nordisk A/s


 Factor viii fusion protein patent thumbnailFactor viii fusion protein
The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated factor viii molecules fused to a polypeptide such as e.g.
Novo Nordisk A/s


 Novel albumin-free factor viii formulations patent thumbnailNovel albumin-free factor viii formulations
A factor viii composition formulated without albumin, comprising the following formulation excipients in addition to factor viii: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8.
University Of Connecticut


 Factor viii compositions and methods of making and using same patent thumbnailFactor viii compositions and methods of making and using same
The present invention relates to compositions comprising factor viii coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor viii-related diseases, disorders, and conditions.. .
Amunix Operating Inc.


 Lipid nanodiscs and nanorods as modulators of clotting factor function in vivo patent thumbnailLipid nanodiscs and nanorods as modulators of clotting factor function in vivo
The present invention includes composition and methods of using a lipid nanodisk or nanotube composition comprising a lipid composition of phosphatidylserine and galactosylceramide and a membrane-bound factor viii protein, a membrane-bound factor ix protein, a membrane-bound factor viii-factor ix protein complex, or a membrane-bound factor v-factor x protein complex in or about the lipid nanodisks or nanotubes.. .
Board Of Regents, The University Of Texas System


 Method for improving the stability of purified factor viii after reconstitution patent thumbnailMethod for improving the stability of purified factor viii after reconstitution
The present disclosure relates to a method for increasing the stability of a factor viii molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the factor viii molecule into a first fragment comprising essentially the a1 domain and the a2 domain and a second fragment comprising essentially the a3 domain, the c1 domain and the c2 domain throughout manufacturing the factor viii molecule. The disclosure further pertains to a method for improving the bioavailability of factor viii after intravenous and non-intravenous injection..
Csl Limited


 Recombinant factor viii proteins patent thumbnailRecombinant factor viii proteins
Provided are recombinant factor viii proteins, e.g., human factor viii proteins with heterologous moieties inserted into flexible permissive loops located in the factor viii a domains, while retaining the procoagulant activity of factor viii.. .
Biogen Idec Ma Inc.


 Process for producing and purifying factor viii and its derivatives patent thumbnailProcess for producing and purifying factor viii and its derivatives
Disclosed is a method for producing proteins having factor viii procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate.
Sk Chemicals Co., Ltd.


 A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag patent thumbnailA process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
A process for manufacturing of a factor viii product having a ratio of fviii:c/fviii:ag of at least 0.7 in the factor viii product by using chromatography wherein at least one chromatographic step is performed by means of employing; an affinity chromatography resin having an affinity for specifically binding of factor viii which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kd yeast derived fab antibody fragment directed to the factor viii molecule. An anionic chromatography resin.
Octapharma Ag


Recombinant factor viii proteins

Provided are recombinant factor viii proteins, e.g., human factor viii proteins, in which one or more amino acids in at least one permissive loops or a3 domain are substituted or deleted, or replaced with heterologous moieties, while retaining the procoagulant activity of factor viii.. .
Biogen Ma Inc.

Methods and assays for factor viii activity

The methods and compositions described herein relate to the measurement of factor viii (fviii) levels and/or activity.. .
The U.s. Government As Represented By The Departme Nt Of Veterans Affairs

Stabilized factor viii variants

The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized factor viii molecules conjugated with a half life extending moiety as well as use of such molecules..
Novo Nordisk A/s

Targeted delivery of factor viii proteins to platelets

The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human factor viii or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.. .
Novo Nordisk A/s

Cell culture processes

Culturing heterologous protein-secreting mammalian cells, such as cho or bhk cells, at 35.1-36.5° c. And/or at ph 7.15-7.20 and/or at a dissolved co2 concentration of 10% or lower.
Baxalta Gmbh

Optimized human clotting factor viii gene expression cassettes and their use

The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to factor viii proteins containing modifications in the amino acid sequence of the factor viii protein, as well as nucleic acid constructs encoding the factor viii proteins and methods of using these compositions to treat a bleeding disorder..
The University Of North Carolina At Chapel Hill

Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii

Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
Chugai Seiyaku Kabushiki Kaisha

Conjugated factor viii molecules

The present invention relates to b-domain truncated factor viii molecules with a modified circulatory half-life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules..
Novo Nordisk A/s

Method of treating haemophilia by inducing tolerance to blood factors

The present invention relates to the treatment of haemophilia. More specifically, the invention relates to a new method of inducing an immune tolerance against at least one blood factor used to treat haemophilia through the epicutaneous route by application of a skin patch device comprising a blood factor in order to continue haemophilia treatment.
Inserm (institut National De La Sante Et De La Recherche Medicale)

Compounds suitable for treatment of haemophilia

The present invention relates to von willebrand (vwf) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a factor viii molecule and (ii) a vwf compound..
Novo Nordisk A/s

Factor viii: remodeling and glycoconjugation of factor viii

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.. .
Novo Nordisk A/s

Complex

The present invention relates to a covalent complex of von willebrand factor (vwf) and factor viii, wherein the complex is modified such that it has an extended half-life in vivo. The invention further relates to a method of producing the complex, as well as the therapeutic or prophylactic use of the complex for treating or preventing bleeding events..
Csl Limited

Factor viii zwitterionic polymer conjugates

The present invention provides multi-armed high mw polymers containing hydrophilic groups conjugated to factor viii, and methods of preparing such polymers.. .
Kodiak Sciences Inc.

Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

The present invention provides methods of administering factor viii; methods of administering chimeric and hybrid polypeptides comprising factor viii; chimeric and hybrid polypeptides comprising factor viii; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.. .
Biogen Hemophilia Inc.

Factor viii-xten fusions and uses thereof

The present invention provides chimeric proteins comprising a factor viii (fviii) polypeptide and xten polypeptides. The fviii polypeptide can have a reduced affinity for von willebrand factor (vwf).
Amunix Operating Inc.

Factor viii: remodeling and glycoconjugation of factor viii

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.. .
Novo Nordisk A/s



Factor Viii topics:
  • Factor Viii
  • Nucleotide
  • Antibodies
  • Polynucleotide
  • Polypeptide
  • Sialic Acid
  • Circulatory
  • Recombinant
  • Ethylene Glycol
  • Coagulation
  • Hemophilia
  • Physiologic
  • Endogenous
  • Prophylaxis
  • Blood Coagulation


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Factor Viii for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor Viii with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.8196

    file did exist - file did put1224

    5 - 1 - 26